Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study], Rev Neurol (Paris), vol.164, pp.6-7588, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00476651
Epidemiology of primary brain tumors: Current concepts and review of the literature, Neuro-Oncology, vol.4, issue.4, pp.278-99, 2002. ,
DOI : 10.1215/15228517-4-4-278
Biology of angiogenesis and invasion in glioma, Neurotherapeutics, vol.2, issue.3, pp.447-57, 2009. ,
DOI : 10.1016/j.nurt.2009.04.001
CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study, Neuro Oncol, vol.8, issue.2, pp.189-93, 2006. ,
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan, 8. stark-vance. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, pp.329-365, 2009. ,
DOI : 10.1007/s11060-008-9718-y
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, Clin Cancer Res J Clin Oncol, vol.1325, issue.1030, pp.1253-94722, 2007. ,
Response criteria for phase II studies of supratentorial malignant glioma Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging, J Clin Oncol Radiology, vol.8211, issue.123, pp.1277-80791, 1990. ,
Relative Cerebral Blood Volume Measurements in Intracranial Mass Lesions: Interobserver and Intraobserver Reproducibility Study, Radiology, vol.224, issue.3, pp.797-803, 2002. ,
DOI : 10.1148/radiol.2243011014
Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomasValue of relative cerebral blood volume measurement using perfusion MRI in glioma management], Curr Opin Neurol Neurochirurgie, vol.2154, issue.154, pp.728-35503, 2008. ,
NMR perfusion imaging: applications to the study of brain tumor angiogenesis], Bull Acad Natl Med, vol.184, issue.3, pp.557-67, 2000. ,
Place de l???imagerie de perfusion par irm dans la prise en charge des tumeurs c??r??brales, gliales en particulier, Neurochirurgie, vol.51, issue.3-4, pp.287-98, 2005. ,
DOI : 10.1016/S0028-3770(05)83490-3
Is perfusion imaging useful for the characterization of brain tumors?] Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors, J Neuroradiol Radiology, vol.34249, issue.192, pp.287-9601, 2007. ,
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy Novel anti-angiogenic therapies for malignant gliomas, Clin Cancer Res Lancet Neurol, vol.157, issue.22, pp.4589-991152, 2008. ,
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1., Molecular and Cellular Biology, vol.16, issue.9, pp.4604-4617, 1996. ,
DOI : 10.1128/MCB.16.9.4604
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma, Cancer Research, vol.64, issue.19, pp.7011-7032, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1364
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Invasion as limitation to anti-angiogenic glioma therapy Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis, Cancer Res Acta Neurochir Suppl Leenders WP, Kusters B, de Waal RM Endothelium, vol.61889, issue.272, pp.6624-6632, 2001. ,
An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study], Rev Neurol (Paris), vol.164, pp.6-7588, 2008. ,
New place of the chemotherapy in gliomas], Bull Cancer, vol.92, issue.4, pp.343-54, 2005. ,
[Perspectives in diagnosis and management of malignant gliomas], Cancer Radiother, vol.12, pp.6-7695, 2008. ,
Epidemiology of primary brain tumors: Current concepts and review of the literature, Neuro-Oncology, vol.4, issue.4, pp.278-99, 2002. ,
DOI : 10.1215/15228517-4-4-278
WHO Classification of Tumours of the Central Nervous System, N Engl J Med, vol.352, issue.6, pp.987-96, 2005. ,
Observer reliability in histological grading of astrocytoma stereotactic biopsies, Journal of Neurosurgery, vol.85, issue.6, pp.1091-1095, 1996. ,
DOI : 10.3171/jns.1996.85.6.1091
Histological and molecular classification of gliomas], Rev Neurol (Paris), vol.164, pp.6-7505, 2008. ,
An integrated genomic analysis of human glioblastoma multiforme A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma, Cancer Res Science Cancer Res, vol.6432166, issue.1220, pp.6892-91807, 2004. ,
Molecular pathogenesis of oligodendroglial tumors, Journal of Neuro-Oncology, vol.62, issue.2, pp.161-81, 2004. ,
DOI : 10.1007/s11060-004-2748-1
Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets, The American Journal of Pathology, vol.161, issue.1, pp.313-322, 2002. ,
DOI : 10.1016/S0002-9440(10)64183-1
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making, J Natl Cancer Inst J Neurosurg, vol.90104, issue.164, pp.1473-9542, 1998. ,
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-60, 2006. ,
DOI : 10.1038/nature05236
Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor, Cancer Research, vol.66, issue.16, pp.7843-7851, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1010
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, Mol Cancer Lancet J Clin Oncol, vol.534526, issue.2125, pp.671008-124189, 1995. ,
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis, J Clin Oncol Lab Invest, vol.2480, issue.236, pp.2707-14837, 2000. ,
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas, Journal of Clinical Neuroscience, vol.16, issue.9, pp.1119-1149, 2009. ,
DOI : 10.1016/j.jocn.2009.02.009
CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study, Neuro Oncol, vol.8, issue.2, pp.189-93, 2006. ,
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, 30. stark-vance. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma, pp.329-361253, 2007. ,
Response criteria for phase II studies of supratentorial malignant glioma., Journal of Clinical Oncology, vol.8, issue.7, pp.1277-80, 1990. ,
DOI : 10.1200/JCO.1990.8.7.1277
Perfusion MR imaging for initial diagnosis and follow-up of brain tumors]MR and CT perfusion imaging of the brain: principles and clinical applications] Pt 2):444-71. 35. Sorensen. Cerebral MR perfusion imaging. Priciples and current applications Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrastenhanced perfusion MR imaging with glioma grade, -4 Pt 2):287-98. 34. Grand S, pp.746-55, 2000. ,
Dynamic susceptibility contrast MRI of gliomas Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging, Neuroimaging Clin N Am Radiology, vol.12211, issue.43, pp.501-23791, 1999. ,
Relative Cerebral Blood Volume Measurements in Intracranial Mass Lesions: Interobserver and Intraobserver Reproducibility Study, Radiology, vol.224, issue.3, pp.797-803, 2002. ,
DOI : 10.1148/radiol.2243011014
Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomasValue of relative cerebral blood volume measurement using perfusion MRI in glioma management], Curr Opin Neurol Neurochirurgie, vol.2154, issue.64, pp.728-35503, 2008. ,
NMR perfusion imaging: applications to the study of brain tumor angiogenesis], Bull Acad Natl Med, vol.184, issue.3, pp.557-67, 2000. ,
Is perfusion imaging useful for the characterization of brain tumors?] Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors, J Neuroradiol Radiology, vol.34249, issue.442, pp.287-9601, 2007. ,
Microscopic susceptibility variation and transverse relaxation: theory and experiment Vessel size imaging, Magn Reson Med Magn Reson Med, vol.3145, issue.63, pp.397-408, 1994. ,
[Perfusion MR imaging in brain tumors]Advances in adults' gliomas biology, imaging and treatment], J Radiol Pt Bull Cancer, vol.8797, issue.481, pp.807-2117, 2006. ,
Perfusion Imaging Using Arterial Spin Labeling, Topics in Magnetic Resonance Imaging, vol.15, issue.1, pp.10-27, 2004. ,
DOI : 10.1097/00002142-200402000-00003
Magnetic resonance imaging of angiogenesis in tumors]Cerebral gliomas: imaging diagnosis and follow-up], J Radiol J Radiol, vol.8887, issue.36 2, pp.779-91, 2006. ,
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected], AJNR Am J Neuroradiol, vol.25, issue.2, pp.214-235, 2004. ,